Cyprotex Share Discussion Threads

[saturn5] 29/12/2015 22:46

The rise in the share price is sudden and rapid

Good news will be on its way

[saturn5] 29/12/2015 22:46

The rise in the share price is sudden and rapid

Good news will be on its way

[rrb] 29/12/2015 12:06

On decent volume too...

[p1nkfish] 29/12/2015 11:10

I wonder what will happen if they discover any unpleasant effects from commonly used chemicals not yet thoroughly tested? Manufacturers of alternatives could boom.

This rise is something special.

[buywell3] 29/12/2015 01:04

Re above

Cyprotex can now offer a 3D version of CellCiphr


!0,000 chemical compounds need testing by the EPA

[buywell3] 29/12/2015 01:01

CellCiphr is part of the IP that Cyprotex owns


ToxCast™ publish CellCiphr® research on the prediction of cellular damage and repair

High Content Screening in HepG2 Cells

Posted 16th December 2015 by Cyprotex

ToxCast™ is a research initiative launched in 2007 by the United States Environmental Protection Agency (US EPA) to screen compounds and gain insight into their toxicological profiles.

To date, more than 1800 chemicals have been assessed in high-throughput assays and the data catalogued and released to the public. Cyprotex’s US laboratory in Watertown, MA (previously named Apredica) have contributed to the High Content Imaging (HCI) research for the ToxCastTM project.

The US EPA recently published the results of this study with Apredica, which used Cyprotex’s HCI platform, CellCipr®, to elucidate cell damage caused by chemicals and at which point (either through concentration or exposure time) cells would no longer recover from the damage sustained. The study assessed phenotypic changes of 11 endpoints caused by 967 chemicals at a range of concentrations (up to 200 µM) over a 72 hour exposure period in HepG2 cells. The endpoints included p53, c-Jun, phospho-histone H3, alpha tubulin, mitochondrial membrane potential, mitochondrial mass, cell cycle arrest, nuclear size and cell number. To better understand the toxic properties of these test articles, the rate at which cells reached damage beyond repair, or a “tipping point”, was quantified. Unsurprisingly, compound concentration played a direct role in the speed with which this tipping point was reached. The results broke out quite neatly, with about one-third each showing either irreparable damage, resilience or need for further analysis.

However, there are some notable limitations to this study. First, HepG2 cells are not hepatocytes and as such, behave differently, in part because of their relatively lower metabolic activity. Furthermore, because this study was performed in a 2D monoculture, some of the nuances expressed in a multi cell-type organ may not have been expressed. Additionally, only two time points where examined – 24 and 72-hour. While a little more than one-third of the compounds reached or surpassed the phenotypic tipping point at 72 hours, one-third did not. A subset of the cells that showed recovery capabilities (that is, repairable damage) had not fully recovered by 72 hours. It remains unknown whether recovery would have continued beyond that or maximum, though incomplete, restoration was achieved.

Despite these limitations, the findings demonstrate the utility of High Content Imaging for detection of toxicological response and providing an insight into adaptation and resilience of in vitro cellular systems based on tipping point analysis. It is proposed that this technique has the potential for defining risk-based prioritisation of chemicals.

[buywell3] 29/12/2015 00:58

Ref other contracts that Cyprotex and USA companies that Cyprotex have acquired that won EPA contracts.

Contracts that Cyprotex continue to work upon ( 5 years duration when signed )


This bodes well for more in vitro chemical compound testing including endocrine disruptor testing as well as toxicity testing





US Senate Passes Bill to Reform Toxic Substance Control Act (TSCA)
In vitro Services

Posted 22nd December 2015 by Cyprotex

In December 2015, the United States Senate voted unanimously in favour of passing S.697 (the Frank R Lautenberg Chemical Safety of the 21st Century Act) for reform to the Toxic Substances Control Act (TSCA).

The overall intention of the reform is to better protect human health and the environment from unsafe chemicals. Consumer safety groups acknowledge the change is largely for the better, with new provisions that give the US Environmental Protection Agency (EPA) power to work directly with companies by ordering tests and imposing restrictions if necessary.

Other key additions include:

An enforceable schedule for EPA chemical reviews
Collection of fees from industry for funding of the work of the EPA.
A priority on assessing persistent, bioaccumulative and toxic chemicals and on specific vulnerable groups

The Senate bill will now be reconciled with the House of Representative’;s TSCA reform bill (H.R. 2576, the TSCA Modernization Act) which was passed in June 2015.

It is expected that the reconciled bill will be signed into law by the President in early 2016.

[buywell3] 29/12/2015 00:54

Re a decent contract

Lab Assistants are used to load up to prepare the unit compound test wells ( circa 96 wells per unit for use in the robotics platforms, among other duties.

Thus the increase in vacancies for these positions translates well in terms of work volumes.... ie contracts/sizes.

The impetus referred to in the update for the last quarter should in my mind follow through as the vacancies suggest.






Current Positions

Senior Scientist - Watertown, MA

Laboratory Assistant(s) Permeability Team - Macclesfield, UK

Laboratory Assistant(s) (12 month contract) - Macclesfield, UK

Research Assistant – Scientific Computing (Part time, Macclesfield)

[p1nkfish] 23/12/2015 19:04

Whatever, I'm not selling. Getting out is easy. Back in at my volume a real problem.

[husbod] 23/12/2015 10:57

Extremely tightly held methinks p1inkfish. The question now is whether the results, which presumably will be in mid April, will live up to expectations or whether the old saying will kick in - better to travel than arrive. Given the y/e is in a few days time I suppose we might get a further update before the actual results.

[p1nkfish] 22/12/2015 11:41

Tightly held.
Still here and indend to hold post loan note.
Not sensible to consider timing or trading it.

[buywell3] 21/12/2015 23:55

Maybe Cyprotex have been awarded a decent sized contract

BIG Pharma's don't like their name or details of such being broadcast

So we can only wait and see what the turnover has grown to

None the less 2015 looks like being a very good year for the company and the BOD have steadied the ship as well as plotting a new course towards prosperity.

I look forwards to 2016 for more of the same with a reasonable expectation that the momentum gained in this last quarter will feed through into 2016.

The next acquisition will be an important one

My guess is that it will be a 'fit' to the BOD's new drive towards BioSciences & Computer modelling


My guess re olde PI's is that around 75% have sold out

[rrb] 21/12/2015 22:28

Husbod - I'm still here! Patiently holding. We need to get rid of the loan note overhang. Then we can think about much higher numbers. They are growing revenues and maintaining margins while also investing. When it all comes together this thing will be 3-4 x current levels in my view.

Patiently holding!!

[p1nkfish] 21/12/2015 17:48

How to know a fair value when tbe level they exceed market expectations by is known? A big word - significant. This is also whilst the US may still be less than 100% running smoofhly. What happens when the US is ok?


'the Board expects that its full year EBITDA will significantly exceed current market expectations'

[p1nkfish] 21/12/2015 16:58

Most probably know why they own this. A busy BB is an alarm ringing that we bave traders onboard. The rise is a little scary looking at that plot but it might stick this time. Good luck everyone. If it doesn't stick this time it will one day. I see this well north of £1.20 sometime and Baxter getting his deserved options.

[husbod] 21/12/2015 16:33

This board is very quiet given the rise we've enjoyed over the last month or so. Do we have a load of lurkers or did most of the PIs give up a year or so ago.

[p1nkfish] 21/12/2015 10:00

Hope they stash the cash for a while before embarking on any further acquisitions.
It will do no harm to have cash at hand.

[saltaire111] 21/12/2015 09:47

Blimey! Going through the roof. A one-bagger for me! Happy Christmas thanks to CRX.

Salty.

[buywell3] 20/12/2015 22:16

My 1M GBP profit call for this year looks to be on

Cyprotex are obviously winning more orders/work

No doubt the recent RNS's detailing their new computer based offerings, and their other various in vitro assays have hit the mark clients were looking at.

The CRX chart looks distinctly healthy , as does that of SBS

Both are beating the hell out of the FTSE100 index

Which I seem to remember a former poster here pushing stocks in as a better bet than the likes of CRX and SBS

Sorry would be nice

[rrb] 17/12/2015 17:05

£11m retained deficit?

[ch4p_85] 17/12/2015 13:21

Think this may be a wee bit overvalued tbh. Considering they have an 11m retained deficit and 4m in the bank. Even when factoring in the ebitda growth that is expected. BWtfdik

[red army] 17/12/2015 13:08

It would have been helpful if they said why??????

[husbod] 17/12/2015 09:31

Share price significantly ahead of expectations!

Or at least the expectations that followed the original wildly optimistic expectations a few years back

£1 at Xmas would be more than acceptable.

[timtom2] 17/12/2015 09:30

Cyprotex PLC (AIM: CRX), the preclinical ADME-Tox services company, provides an update on revenue and profit guidance for the year to 31 December 2015.


Trading update



The financial performance of the Company for the last quarter of the year is ahead of expectations and the Board expects that its full year EBITDA will significantly exceed current market expectations.